SeHCAT (tauroselcholic [75selenium] acid) is recommended by NICE for use in research to collect more information about its usefulness in the diagnosis and treatment of bile acid malabsorption.
SeHCAT, a radioactive drug, is the only test currently used to diagnose bile acid malabsorption, which can cause long-lasting debilitating diarrhoea. NICE assessed the use of SeHCAT to help the NHS decide whether to use this product for investigating diarrhoea due to bile acid malabsorption in people with diarrhoea-predominant irritable bowel syndrome and in people with Crohn’s disease who have not had ileal resection. NICE concluded that that SeHCAT is potentially useful in this setting, but that there is not enough evidence to work out whether it is value for money.
This page was last updated: 28 November 2012